Paul Edick

Mr. Edick brought over 35 years of experience in the life sciences industry to PDL when he was elected to the board in September of 2015. Mr. Edick is currently the President and CEO of Xeris Pharmaceuticals, Inc.  Prior to Xeris, he was managing partner of 3G Advisors, LLC. From July 2010 to November 2014, he served as chief executive officer and a board member of Durata Therapeutics, Inc. Prior to his term at Durata, Mr. Edick was chief executive officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus investment search vehicle, from 2008 to 2010 and prior to that was chief executive officer at MedPointe Healthcare, Inc., a position he assumed in 2006 having been their president of pharmaceutical operations from 2002. He also held a number of senior positions at GD Searle & Company, and at Pharmacia Corporation following its acquisition of the company, culminating in his appointment as Pharmacia’s group VP and president, Asia Pacific/Latin America. Mr. Edick currently serves on the boards of directors for Sucampo Pharmaceuticals Inc., NewLink Genetics Corporation and, Neos Therapeutics, Inc. all of which are public companies. He also serves on the Board of the private company Amerita, Inc. Mr. Edick holds a B.A. in Psychology from Hamilton College. Mr. Edick brings to the Board over 35 years of experience in the life sciences industry, including extensive development and commercial expertise from his chief executive officer positions at several companies, including most recently at Xeris Pharmaceuticals, Inc. and Durata Therapeutics, Inc.